Guest
Medicenna is a clinical stage immunotherapy company that uses engineered interleukins that can modulate, fine-tune or amplify the immune system for the treatment of a range of cancers. • MDNA11 is a next-generation immunotherapy that has shown impressive preclinical data in boosting cancer-killing immune cells. o 200x superior CD122 binding without CD25 affinity, i.e. higher efficacy and much lower toxicity than standard of care (SOC). o In Dec 2019, Sanofi won a bidding war to acquire Synthorx, which has an IL-2 product candidate, for US$. MDNA11 is earlier stage but has shown more promising results. By the end of 2021 MDNA will be at a similar stage of development to Synthoryx when they were acquired. • MDNA55 has gone through a Phase 2b clinical trial for recurrent glioblastoma (rGMB), the most common and fatal form of brain cancer. Results were extremely promising, suggesting significant improvements in efficacy vs. standard of care. With MDNA55, average survival was 11.6 months v
